Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
ImmunityBio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
IBRX
Nasdaq
2836
immunitybio.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for ImmunityBio, Inc.
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer
- Jan 29th, 2025 1:30 pm
Exploring High Growth Tech Stocks in the United States
- Jan 28th, 2025 6:03 pm
ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
- Jan 27th, 2025 2:00 pm
ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency
- Jan 15th, 2025 10:20 pm
ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom
- Jan 15th, 2025 10:20 pm
ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective
- Jan 6th, 2025 2:00 pm
High Growth Tech Stocks to Watch in December 2024
- Dec 30th, 2024 6:06 pm
D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering
- Dec 12th, 2024 1:00 pm
ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock
- Dec 11th, 2024 12:30 pm
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock
- Dec 10th, 2024 9:24 pm
Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge Funds
- Nov 23rd, 2024 3:24 pm
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
- Nov 21st, 2024 3:00 pm
High Growth Tech Stocks To Watch In November 2024
- Nov 20th, 2024 2:02 pm
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
- Nov 19th, 2024 1:00 pm
ImmunityBio Reports Third-Quarter 2024 Financial Results
- Nov 12th, 2024 12:15 pm
ImmunityBio Soars 56% in a Day: Is This Cancer Breakthrough the Next $30 Stock?
- Oct 25th, 2024 7:22 pm
First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
- Oct 24th, 2024 1:00 pm
ImmunityBio to Participate in the Jefferies London Healthcare Conference
- Oct 21st, 2024 1:00 pm
ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
- Sep 9th, 2024 12:30 pm
ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval
- Aug 12th, 2024 12:46 pm
Scroll